Gilteritinib Received FDA Approval for Treating Refractory or Relapsed Acute Myeloid Leukemia

The US Food and Drug Administration (FDA), FLT3 mutation-positive relapsed (recurrent) or refractory (treatment-resistant) acute myeloid leukemia (AML) in adult patients, for treatment, approved gilteritinib (brand name Xospata, company Astellas Pharma), a small-molecule targeted oral tablet, a cancer pill, on 28 November 2018.
The LeukoStrat CDx FLT3 Mutation Test, developed by Invivoscribe Technologies to detect FLT3 mutations, was also approved.
Approximately % 25 to 30 of patients with AML have an FLT3 gene mutation, which in AML is associated with a particularly aggressive disease form and a higher risk of relapse (recurrence).
Gilteritinib is the first medicine approved as monotherapy (single-drug treatment) in patients with FLT3 mutation-positive AML.
Approval is based on a randomized trial in FLM3-positive relapsed / refractory AML involving 138 adult patients who took 120 mg of gilteritinib orally daily, a phase 3 clinical trial called ADMIRAL . In this group, % 21 of patients achieved partial complete recovery or complete remission with partial hematologic recovery.
In addition, among 106 patients initially needing red blood cell or platelet transfusions, % 31 did not require transfusions for at least 56 days.
The ADMIRAL study is ongoing, and detailed response and overall survival data are expected to be released publicly during the coming year.
Another clinical trial evaluating gilteritinib efficacy in AML, whose results in 2017 were published in The LANCET Oncology, was CHRYSALIS . In this study involving 252 patients, at phase 1/2, among patients with relapsed or refractory FLT3 mutation-positive AML, % 49 were observed to respond to gilteritinib. Median survival for these patients exceeded 7 months.
Data from CHRYSALIS also showed that the medicine was generally well tolerated, and the most common adverse effectsattributed to gilteritinib were, in 41 patients (% 16), diarrhea, in 37 patients (% 15), fatigue and, in 33 patients (% 13), elevated AST and ALT levels. These were generally mild, and only 25 patients (% 10) stopped treatment because of adverse effects.
Although we await ADMIRAL's final analysis, available gilteritinib data suggest that adverse effects are fewer and milder than with conventional chemotherapy. Also, because gilteritinib is taken orally as a pill, it allows outpatient treatment.
Considering that, to date, there have been no other meaningful options beyond chemotherapy for AML treatment, this approval brings a highly effective and well-tolerated treatment option.
Sources
fda.gov - 28 November 2018.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.